HONG KONG – Having recently completed the acquisition of Belgium-based Ogeda SA, Astellas Pharma Inc. now has a potentially key drug candidate at its disposal as well as access to new programs to its drug development pipeline, all of which could provide boosts to its bottom line as it deals with an imminent patent cliff. (See BioWorld Today, April 4, 2017.)